Statements (39)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:Company
|
| gptkbp:acquired |
gptkb:Hologic,_Inc.
|
| gptkbp:awards |
multiple industry awards
Frost & Sullivan Award for Technology Innovation |
| gptkbp:ceo |
Carl Hull
|
| gptkbp:clinical_trial |
diagnosis of cancer
diagnosis of respiratory infections diagnosis of sexually transmitted infections |
| gptkbp:collaborations |
academic institutions
|
| gptkbp:employees |
approximately 1,000
|
| gptkbp:founded |
gptkb:1983
|
| gptkbp:founder |
gptkb:Jack_W._Szostak
|
| gptkbp:global_presence |
operates in multiple countries
|
| gptkbp:headquarters |
gptkb:San_Diego,_California
|
| https://www.w3.org/2000/01/rdf-schema#label |
Gen-Probe
|
| gptkbp:industry |
medical diagnostics
|
| gptkbp:innovation |
leader in molecular diagnostics
|
| gptkbp:notable_achievement |
first FDA-approved test for detecting HIV-1
first FDA-approved test for detecting HPV. first FDA-approved test for detecting chlamydia first FDA-approved test for detecting gonorrhea |
| gptkbp:notable_work |
HIV tests
chlamydia tests |
| gptkbp:partnerships |
various healthcare organizations
various pharmaceutical companies |
| gptkbp:products |
nucleic acid tests
|
| gptkbp:regulatory_compliance |
FDA approved products
|
| gptkbp:research_and_development |
significant investment in R& D
|
| gptkbp:research_focus |
molecular diagnostics
infectious diseases |
| gptkbp:revenue |
$400 million (2012)
$400 million (2011) |
| gptkbp:services |
molecular diagnostics
|
| gptkbp:subsidiary |
Prodesse, Inc.
|
| gptkbp:symbol |
GPRO
|
| gptkbp:technology |
proprietary nucleic acid probe technology
|
| gptkbp:website |
www.gen-probe.com
|
| gptkbp:bfsParent |
gptkb:Hologic
|
| gptkbp:bfsLayer |
4
|